Prevtec Microbia is proud to announce that it recently submitted a dossier to the European regulatory authorities, for the approval of its Coliprotec® F4/F18. This live bacterial vaccine for oral administration will offer a broader spectrum than the Coliprotec F4 vaccine presently available in the European Union. It will allow for the immunization of pigs against both E. coli enterotoxinogenic F4 and E. coli enterotoxinogenic F18 bacteria associated with post-weaning diarrhea in swine. Coliprotec F4/F18 will therefore contribute to the reduction of antibiotic use in European swine operations.
Prevtec Microbia’s scientific and regulatory team has successfully managed this filing and takes this opportunity to underscore the support of its partners, Elanco and Klifovet in making this project successful.